Endometrial intraepithelial carcinoma (EIC) is a rare pathologic variant of uterine serous carcinoma (USC). Our aim is to distinguish patterns of clinic–pathologic outcomes in patients with EIC and USC for disease limited to the endometrium (stage 1A) as well as with distant metastasis (stage 4B). Surgically staged patients were retrospectively identified and relevant variables were extracted and compared. Kaplan-Meier was used to generate the survival data. More USC (n = 29) exhibited lymphovascular invasion (stage 4, P = .01) and expressed higher levels of estrogen receptor-α than EIC (P = .0009 and .063 for stages 1 and 4, respectively). The survival is comparable, with 1 recurrence in each group for stage 1A disease. For stage 4 EIC and USC, the progression-free survival (14 vs10 months) and overall survival (19 vs 20 months) are similar to what is previously published. In conclusion, EIC, whether limited to the endometrium, or widely metastatic, imparts similar outcomes and should be treated comparably with stage-matched USC.
HowladerN NAKrapchoMNeymanN (eds). SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institue; 2011.
3.
BorutaDM2ndGehrigPAFaderANOlawaiyeAB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115(1):142–153.
4.
HamiltonCACheungMKOsannKUterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642–646.
MaxwellGLTianCRisingerJRacial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer. 2006;107(9):2197–2205.
7.
ShermanMEDevesaSS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003;98(1):176–186.
8.
UedaSMKappDSCheungMKTrends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008;198(2):218 e1–218 e6.
HendricksonMRossJEifelPMartinezAKempsonR. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6(2):93–108.
11.
CarcangiuMLChambersJT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol. 1995;14(1):30–38.
12.
O'HanlanKALevinePAHarbatkinDVirulence of papillary endometrial carcinoma. Gynecol Oncol. 1990;37(1):112–119.
13.
AmbrosRAShermanMEZahnCMBittermanPKurmanRJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26(11):1260–1267.
14.
ShermanMEBittermanPRosensheinNBDelgadoGKurmanRJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol. 1992;16(6):600–610.
15.
SlomovitzBMBurkeTWEifelPJUterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91(3):463–469.
16.
WheelerDTBellKAKurmanRJShermanME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24(6):797–806.
ZhengWLiangSXYiXUlukusECDavisJRChambersSK. Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. Int J Gynecol Pathol. 2007;26(1):38–52.
20.
EinsteinMHFrimerMKuoDYPhase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. Gynecol Oncol. 2012;124(1):21–25.
21.
FieldsALEinsteinMHNovetskyAPGebbJGoldbergGL. Pilot phase II trial of radiation “sandwiched” between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2008;108(1):201–206.
22.
SagrERDenschlagDKerim-DikeniAStanimirGGitschGGilbertL. Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma. Anticancer Res. 2007;27(2):1213–1217.
23.
KatoDTFerryJAGoodmanAUterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol. 1995;59(3):384–389.
24.
HendricksonMRKempsonRL. Surgical Pathology of the Uterine Corpus. Philadelphia, PA: WB Saunders; 1980.
25.
SpiegelGW. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol. 1995;19(4):417–432.
26.
HuiPKellyMO'MalleyDMTavassoliFSchwartzPE. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol. 2005;18(1):75–82.
27.
YanZHuiP. Minimal uterine serous carcinoma with extrauterine tumor of identical morphology: an immunohistochemical study of 13 cases. Appl Immunohistochem Mol Morphol. 2010;18(1):75–79.
28.
ZhengWSchwartzPE. Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol Oncol. 2005;96(3):579–582.
29.
FaderANDrakeRDO'MalleyDMPlatinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer. 2009;115(10):2119–2127.
30.
HavrileskyLJSecordAABae-JumpVOutcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol. 2007;105(3):677–682.
31.
HuhWKPowellMLeathCA3rdUterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol. 2003;91(3):470–475.
32.
DietrichCS3rdModesittSCDePriestPDThe efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2005;99(3):557–563.
33.
RandallTCArmstrongK. Differences in treatment and outcome between African-American and white women with endometrial cancer. J Clin Oncol. 2003;21(22):4200–4206.
34.
PertschukLPMasoodSSimoneJEstrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol. 1996;63(1):28–33.
